ALMR vs BRKR: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BRKR is the larger of the two ($9.78B market cap): the incumbent the market prices for continued execution (26.14x forward earnings, beta 1.27). ALMR is the smaller challenger ($2.18B), priced similarly on forward earnings (-41.92x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ALMR vs BRKR: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricALMRBRKRWhat it tells you
Market cap$2.18B$9.78BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-41.9226.14Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range60% of range87% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book7.164.28How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how ALMR and BRKR affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALMR and BRKR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALMR and BRKR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Alamar Biosciences (ALMR) do?

Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics.

Full ALMR guide

What does Bruker Corporation (BRKR) do?

Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.

Full BRKR guide

ALMR vs BRKR: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ALMR drivers: Consumable pull-through per instrument; Installed base expansion.
  • BRKR drivers: High-end instruments moat; Adjacent growth vectors.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. For BRKR, bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S.

ALMR or BRKR: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALMR if you believe its drivers more; BRKR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALMR and BRKR guides.

ALMR vs BRKR: the full fundamentals

ALMR. There is no meaningful price to earnings ratio because the company loses money, so the market works off revenue multiples: about 18 times trailing sales, or roughly 13 times the 2026 guide once net cash is taken out, down from above 20 times in August. That is still a premium tools multiple for a platform growing north of 50% with widening gross margin. Five analysts carry a mean target near $35.40, and the November 3 report will show whether third-quarter revenue lands near the roughly $30.2 million consensus.

BRKR. Bruker beat EPS estimates in Q1 2026 (~$0.31 versus ~$0.23) and again in Q2 (~$0.49 versus ~$0.38), even as GAAP results stayed negative. The rally of the past year has lifted the forward multiple to roughly 23x, higher than the 15x to 16x it carried in mid-2026, which leaves less cushion if the expected fourth-quarter rebound in research and semiconductor demand comes in light. The average analyst target is about $63.83 from 12 analysts, though JPMorgan's October downgrade set $60.

Headline figures (approximate, October 2026): ALMR shows revenue (ttm) ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year, 2026 revenue guidance ~$116 million to $120 million (consensus ~$119 million), gross margin (ttm) ~59% (Q2 2026 ~60%), net loss (ttm) ~$50 million; Q2 2026 EPS ~-$0.20 vs ~-$0.32 expected; BRKR shows revenue (ttm) ~$3.5B; Q2 2026 revenue ~$838.5M, up ~5.2% YoY, q2 2026 non-gaap eps ~$0.49 vs ~$0.38 consensus, margins Gross ~48.5%, operating ~9.9%; GAAP net margin ~-2% after restructuring and acquisition charges, fy2026 consensus Revenue ~$3.56B, non-GAAP EPS ~$2.12 (prior guidance ~$2.10 to $2.15).

The bottom line: ALMR vs BRKR

ALMR and BRKR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALMR and BRKR exposure against your real portfolio. It is not an investment adviser.

Wondering how ALMR or BRKR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Alamar Biosciences

Ask Walnut's AI anything about ALMR and see how it fits what you own.

FAQ

What is the difference between ALMR and BRKR?

+

Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ALMR or BRKR the better stock?

+

Neither is universally better. BRKR is the larger incumbent; ALMR is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ALMR or BRKR?

+

On forward P/E (as of November 2026), ALMR trades at -41.92x and BRKR at 26.14x, so ALMR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ALMR and BRKR?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ALMR vs BRKR?

+

ALMR: Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation still leaves little slack, with the shares near 18 times trailing revenue while the company loses money each quarter, and the 27% fall over the past month shows how hard a small, recently listed stock can reprice without any change in reported numbers. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which falls in mid-October 2026 and can put additional shares into a thinly traded float. The November 3 third-quarter report is the next test of the $116 million to $120 million full-year guide. BRKR: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. and international research funding directly pressure demand, and organic revenue has been declining as a result. The company flagged an approximately $100 million revenue headwind and $90 million operating-profit impact tied to academic funding disruptions. Heavy acquisition activity introduces integration risk and can mask organic softness, while a large, more diversified competitor in Thermo Fisher can outspend Bruker across the portfolio. Supply-chain exposure to items like high-performance memory chips and liquid helium, plus U.S.-China trade and geopolitical tensions, add further uncertainty. Turning frontier technologies into repeatable, high-volume commercial revenue remains an ongoing execution challenge. Near term, the full-year numbers depend on a large fourth quarter (consensus near $1.03 billion of revenue versus about $838.5 million in the second quarter), so any slip in that rebound would land directly on guidance. Leverage has also risen with acquisitions, to about $1.86 billion of debt against roughly $185 million of cash.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALMR or BRKR; figures are approximate and dated (as of November 2026). Verify current data before investing.